Anand Jillella

Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells

Warren Fiskus, Yongchao Wang, Arun Sreekumar et al. · Blood · 2009 · 358 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML

Amir T. Fathi, Harry P. Erba, Jeffrey E. Lancet et al. · Blood · 2018 · 105 citations · Full text

Medicine, Oncology, Pharmacology +9

Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease

H. Jean Khoury, Amelia Langston, Vamsi Kota et al. · Bone Marrow Transplantation · 2018 · 87 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +11

Intermediate-Dose versus Low-Dose Cyclophosphamide and Granulocyte Colony-Stimulating Factor for Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Therapies

Mehdi Hamadani, Samith T. Kochuparambil, Salman Osman et al. · Biology of Blood and Marrow Transplantation · 2012 · 72 citations · Full text

Medicine, Hematology, Pharmacotherapy +15

Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KITD816V

Celalettin Üstün, Christopher L. Corless, Natasha M. Savage et al. · Leukemia Research · 2008 · 72 citations

Medicine, Hematology, Oncology +17